Company news from the 10/03/06 News Brief

Share this article:
TAP Pharmaceutical Products has agreed to a co-promotion agreement with Novartis Pharmaceuticals Corporation for Famvir (famciclovir), an oral antiviral prescription medication. Under the terms of the agreement, TAP will be responsible for promoting Famvir to the obstetrician/gynecology (OB/GYN) medical community. Financial terms of the agreement were not disclosed.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in People Moves

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters